The initial $30 million in upcoming user fees for FDA's device surveillance system, the National Evaluation System for health Technology (NEST), isn’t enough to set up the system, and proponents of the massive effort are looking for additional appropriations and private investment to close the funding gap, Mark McClellan and Gregory Daniel, heads of the Duke-Margolis Center for Health Policy, told Inside Health Policy . Daniel pegs the program's cost over the first five years in the hundreds of millions...